Advertisement
Canada markets close in 5 hours 20 minutes

  • S&P/TSX

    21,825.48
    +117.04 (+0.54%)
     

  • S&P 500

    4,993.56
    -17.56 (-0.35%)
     

  • DOW

    37,912.43
    +137.05 (+0.36%)
     

  • CAD/USD

    0.7281
    +0.0018 (+0.24%)
     

  • CRUDE OIL

    83.25
    +0.52 (+0.63%)
     

  • Bitcoin CAD

    88,230.59
    +435.31 (+0.50%)
     

  • CMC Crypto 200

    1,375.22
    +62.59 (+5.01%)
     

  • GOLD FUTURES

    2,403.50
    +5.50 (+0.23%)
     

  • RUSSELL 2000

    1,948.93
    +5.97 (+0.31%)
     

  • 10-Yr Bond

    4.6310
    -0.0160 (-0.34%)
     

  • NASDAQ

    15,440.24
    -161.26 (-1.03%)
     

  • VOLATILITY

    18.81
    +0.81 (+4.50%)
     

  • FTSE

    7,870.93
    -6.12 (-0.08%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     
MARKETS LIVE BLOG:

STOCKS OPEN MIXED AFTER ISRAEL STRIKE-FUELLED TUMBLE

Shares of Netflix, the first of the megacap techs to report, slide in early trading

WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

Reuters
Updated ·1 min read

GENEVA, May 7 (Reuters) - The World Health Organization announced on Friday it had approved a COVID-19 vaccine from China's state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product's safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna. (Reporting by Stephanie Nebehay Editing by Peter Graff)